二甲双胍联合甲地孕酮用于不典型子宫内膜增生和高中分化子宫内膜癌的保留生育治疗:随机对照试验
该单中心随机对照试验纳入150例18-45岁原发性不典型子宫内膜增生(AEH)或高中分化子宫内膜癌(EEC)患者,比较甲地孕酮(MA)单药与MA联合二甲双胍的保留生育治疗效果。主要终点为16周累积完全缓解率,联合组在总体人群中未达统计学显著(34.3% vs 20.7%,P=0.09),但在AEH亚组(39.6% vs 20.4%,P=0.04)、非肥胖AEH亚组(51.4% vs 24.3%,P=0.02)和胰岛素敏感AEH亚组(54.8% vs 28.6%,P=0.04)中显著提高。
要点
- MA联合二甲双胍可提高AEH患者16周完全缓解率,尤其非肥胖和胰岛素敏感者。
- 总体AEH和EEC人群中16周完全缓解率差异未达统计学显著(P=0.09)。
- 30周完全缓解率及不良事件等次要终点无显著差异。
核心结论
- 在AEH患者中,MA联合二甲双胍相比MA单药与更高的早期完全缓解率相关。
研究设计与样本
- 共150例18-45岁原发性AEH或高中分化EEC患者,随机分为MA组(n=74)和MA联合二甲双胍组(n=76)。
主要发现
- 总体16周完全缓解率联合组34.3% vs MA组20.7%(OR 2.0,95%CI 0.89-4.51,P=0.09)。
- AEH亚组16周完全缓解率联合组39.6% vs MA组20.4%(OR 2.56,95%CI 1.06-6.21,P=0.04)。
- 非肥胖AEH亚组16周完全缓解率联合组51.4% vs MA组24.3%(OR 3.28,95%CI 1.22-8.84,P=0.02)。
- 胰岛素敏感AEH亚组16周完全缓解率联合组54.8% vs MA组28.6%(OR 3.04,95%CI 1.03-8.97,P=0.04)。
- 次要终点(30周完全缓解率及不良事件)无显著差异。
关键数值与推荐
- MA用法:160 mg口服,每日一次;二甲双胍用法:500 mg口服,每日三次。
临床怎么用
- 对于AEH患者,尤其是非肥胖或胰岛素敏感者,可考虑MA联合二甲双胍作为保留生育治疗以提高早期缓解率。
局限性
- 单中心、开放标签设计可能引入偏倚。
- 总体人群主要终点未达统计学显著,亚组分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy of metformin in megestrol acetate (MA)-based fertility-sparing treatment for patients with atypical endometrial hyperplasia (AEH) and endometrioid endometrial cancer (EEC). DESIGN: A randomised, single-centre, open-label, controlled trial conducted between October 2013 and December 2017. SETTING: Shanghai OBGYN Hospital of Fudan University, China. POPULATION: A total of 150 patients (18-45 years old) with primary AEH or well-differentiated EEC were randomised into an MA group (n = 74) and an MA plus metformin group (n = 76). METHODS: Patients with AEH or EEC were firstly stratified, then randomised to receive MA (160 mg orally, daily) or MA (160 mg orally, daily) plus metformin (500 mg orally, three times a day). MAIN OUTCOMES AND MEASURES: The primary efficacy parameter was the cumulate complete response (CR) rate within 16 weeks of treatment (16w-CR rate); the secondary efficacy parameters were 30w-CR rate and adverse events. RESULTS: The 16w-CR rate was higher in the metformin plus MA group than in the MA-only group (34.3 versus 20.7%, odds ratio [OR] 2.0, 95% confidence interval [CI] 0.89-4.51, P = 0.09) but the difference was more significant in 102 AEH patients (39.6 versus 20.4%, OR 2.56, 95% CI 1.06-6.21, P = 0.04). This effect of metformin was also significant in non-obese (51.4 versus 24.3%, OR 3.28, 95% CI 1.22-8.84, P = 0.02) and insulin-sensitive (54.8 versus 28.6%, OR 3.04, 95% CI 1.03-8.97, P = 0.04) subgroups of AEH women. No significant result was found in secondary endpoints. CONCLUSION: As a fertility-sparing treatment, metformin plus MA was associated with a higher early CR rate compared with MA alone in AEH patients. TWEETABLE ABSTRACT: For AEH patients, metformin plus MA might be a better fertility-sparing treatment to achieve a higher early CR rate compared with MA alone.
引用
- Yang BY, Gulinazi Y, Du Y, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020. PMID: 31961463. doi:10.1111/1471-0528.16108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。